satavaptan

a vasopressin V2 receptor antagonist; structure given in first source

Also Known As:

1-(4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro(4-(2-morpholinoethoxy)cyclohexane)indoline-2-one, phosphate monohydrate cis-isomer; 1-(4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl)-5-ethoxy-3-spiro-(4-(2-morpholinoethoxy)cyclohexane)indol-2-one fumarate; SR 121463A; SR-121463; SR-121463B; SR121463B

Networked: 34 relevant articles (6 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Watson, Hugh: 15 articles (07/2022 - 07/2008)
2.	Vilstrup, Hendrik: 13 articles (07/2022 - 01/2012)
3.	Jepsen, Peter: 11 articles (07/2022 - 06/2013)
4.	Ginès, Pere: 5 articles (11/2019 - 07/2008)
5.	Wong, Florence: 5 articles (10/2018 - 07/2008)
6.	Bossen, Lars: 3 articles (05/2019 - 01/2016)
7.	Deleuran, Thomas: 2 articles (07/2022 - 01/2022)
8.	Andersen, Per Kragh: 2 articles (01/2019 - 11/2015)
9.	Dam, Gitte: 2 articles (01/2019 - 10/2016)
10.	Bernardi, Mauro: 2 articles (01/2012 - 08/2010)

Related Diseases

1.	Ascites 01/01/2019 - "The HRQL data from previously published randomised controlled trials examining the efficacy of satavaptan in ascites were retrospectively evaluated. " 11/01/2022 - "We developed the Cirrhotic Ascites Severity (CIRAS) model to predict 1-year mortality among 465 patients randomized to placebo in the satavaptan trials investigating treatment of cirrhotic ascites. " 10/01/2016 - "We used data from three 1-year trials of satavaptan for ascites control. " 01/01/2012 - "Nevertheless, some of the secondary efficacy endpoints related to the treatment of ascites were met in the three studies, suggesting a slight advantage of satavaptan over placebo in delaying ascites formation. " 01/01/2012 - "Satavaptan was not more effective than placebo in the control of ascites in any of the populations studied as estimated by the primary efficacy endpoints: worsening of ascites (study 1) and the cumulative number of large-volume paracenteses during 12 weeks (studies 2 and 3). "
2.	Fibrosis (Cirrhosis) 01/01/2012 - "The incidence of major complications of cirrhosis during follow-up did not differ significantly between the satavaptan and placebo groups in the three studies. " 07/01/2022 - "In the satavaptan trial data of 1,198 cirrhosis patients with ascites, the 93 patients with SBP had a cumulative 4-month mortality of 38.6% (95% CI: 29.3-49.7) compared with 11.4% (95% CI: 8.5-15.2) in those without. " 07/01/2022 - "We used Danish healthcare data on cirrhosis patients with a first-time paracentesis in 2000-2014 and data from three randomized controlled trials on satavaptan treatment of ascites conducted in 2006-2008. " 01/01/2022 - "We used data from three randomized trials of satavaptan treatment in patients with cirrhosis and ascites followed for up to 1 year. " 07/26/2016 - "We used data from three randomized 1-year trials of satavaptan in cirrhosis patients with ascites. "
3.	Hyponatremia 11/01/2019 - "Improvement of hyponatremia was more common in patients who received satavaptan (59.7%) than placebo (18.5%). " 11/01/2006 - "The new oral vasopressin V(2)-receptor antagonist satavaptan adequately corrects mild or moderate hyponatremia in patients with SIADH and has a good safety profile." 02/15/2014 - "Satavaptan (SR121463) is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. " 07/01/2008 - "A total of 110 patients with cirrhosis, ascites, and hyponatremia (serum sodium < or =130 mmol/L) were included in a multicenter, double-blind, randomized, controlled study comparing three fixed doses of satavaptan (5 mg, 12.5 mg, or 25 mg once daily) versus placebo. " 08/01/2007 - "In this article, we review results from recent clinical trials on vaptans (lixivaptan, tolvaptan, conivaptan and satavaptan) which showed their efficacy in the treatment of hyponatremia."
4.	Heart Failure 10/01/2001 - "Sanofi-Synthélabo (formerly Sanofi) is developing SR-121463, a vasopressin V, receptor antagonist, as a potential treatment for cardiovascular indications such as congestive heart failure (CHF) and hypertension [330073], [341858]. " 02/15/2014 - "Satavaptan (SR121463) is a vasopressin V2 receptor antagonist that has been shown to improve hyponatremia in patients with cirrhosis, congestive heart failure, and syndrome of inappropriate antidiuresis. " 12/01/2007 - "In clinical trials, conivaptan, lixivaptan, tolvaptan, and satavaptan have increased serum osmolality and normalized the serum [Na(+)] in hyponatremia associated with SIADH, cirrhosis, or congestive heart failure. "
5.	Hepatic Encephalopathy 06/01/2013 - "The objective is to evaluate the efficacy of satavaptan in reducing the risk of new episodes of hepatic encephalopathy. " 06/01/2013 - "Satavaptan did not reduce the frequency of hepatic encephalopathy in patients with cirrhosis and ascites." 06/01/2013 - "Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development." 11/01/2019 - "This is a post-hoc analysis of 250 cirrhosis patients without overt hepatic encephalopathy randomized to receive either placebo or satavaptan, a vasopressin V2 antagonist. "

Related Drugs and Biologics

1.	Vasopressin Receptors (Arginine Vasopressin Receptor)
2.	Tolvaptan
3.	lixivaptan
4.	Diuretics
5.	Vasopressins (Vasopressin)
6.	conivaptan (Vaprisol)
7.	Sodium
8.	Antidiuretic Hormone Receptor Antagonists
9.	Proton Pump Inhibitors
10.	peptide V

Related Therapies and Procedures

1.	Therapeutics